-+ 0.00%
-+ 0.00%
-+ 0.00%
Novartis' Polymyalgia Rheumatica Drug Wins US FDA Nod
Share
Listen to the news
11:19 PM EST, 11/16/2026 (MT Newswires) -- Novartis (NOVN.SW) secured the US Food and Drug Administration's approval for its Cosentyx drug as an alternative to long-term steroid use for adults with polymyalgia rheumatica. The Swiss pharmaceutical company said Tuesday that Cosentyx, or secukinumab, doubled sustained remission rates while helping patients taper off steroids in the phase 3 Replenish trial. The approval makes Cosentyx the first and only anti-interleukin-17 biologic approved for patients with the common inflammatory disease, which mostly affects adults aged 50 and older.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending